Burleson Research Technologies (BRT) is a contract research organization specializing in immune safety, immunotoxicology, and preclinical efficacy research for pharmaceutical, biotechnology, chemical, and medical device organizations.
Founded in 1996 by Drs. Gary and Florence Burleson, Burleson Research Technologies was established with a focus on specialized research in immunotoxicology and immune safety.
For 30 years, BRT has supported pharmaceutical, biotechnology, chemical, and medical device organizations with customized preclinical research. Today, our capabilities span in vivo, in vitro, ex vivo, and bioanalytical approaches, allowing our scientific team to address a wide range of immune safety, function, and efficacy research needs.
Our scientific team brings decades of specialized experience supporting pharmaceutical, biotechnology, and chemical research across immunotoxicology, immune safety, immune function, and preclinical research.
BRT maintains a strong commitment to quality across our preclinical research programs and laboratory operations.
BRT has provided specialized research solutions to clients around the globe since 1996, supporting organizations across the United States and internationally, including Canada, Europe, and Asia.
BRT is located in Morrisville, North Carolina, just minutes from Research Triangle Park and less than five miles from Raleigh-Durham International Airport.
Our approximately 10,000-square-foot facility supports BRT’s in vivo, in vitro, ex vivo, and bioanalytical research capabilities
Whether you have a defined study or are still determining the best approach, BRT’s scientific team can work with you to develop a customized research program based on your objectives.
